Drospirenone - Comprehensive Research Paper

Document Version: 1.0 Last Updated: 2025-12-26 Classification: HRT Research - Female Progestins (Spironolactone Derivative) Paper Number: 39 of 76

1. Summary

1.1 Executive Summary

Drospirenone (DRSP) is a unique synthetic progestin derived from spironolactone rather than testosterone or progesterone, making it pharmacologically distinct from all other progestins used in contraception and hormone replacement therapy. Unlike other progestins that may cause androgenic side effects, drospirenone possesses anti-androgenic and antimineralocorticoid activities that more closely mimic the effects of natural progesterone.

Key Distinguishing Features:

• Spironolactone derivative: Only progestin derived from 17α-spirolactone aldosterone antagonist
• Antimineralocorticoid activity: Equivalent to 25 mg spironolactone per 3 mg dose
• Anti-androgenic activity: Approximately 1/3 the potency of cyproterone acetate
• No androgenic activity: Does not bind androgen receptor as agonist
• No glucocorticoid activity: Unlike some other progestins
• Longer half-life (25-30 hours): Allows 24-hour missed pill window with Slynd

Clinical Applications:

| Application | Products | Key Features | |---

Goal Relevance:

• I want to manage my acne and improve my skin health.
• I'm looking for a birth control option that helps with my PMDD symptoms.
• I need a contraceptive that reduces bloating and fluid retention.
• I want to address hirsutism and reduce unwanted hair growth.
• I'm seeking a hormone replacement therapy to manage menopause symptoms.
• I need a progestin-only pill that offers flexibility with a missed dose.
• I'm looking for a birth control that doesn't cause weight gain or increase my blood pressure.

----------|----------|--------------| | Combined contraception | Yaz, Yasmin, Beyaz, others | EE + DRSP; FDA-approved for acne, PMDD | | Progestin-only contraception | Slynd | First DRSP-only POP; 24-hour window | | Menopausal HRT | Angeliq | E2 + DRSP; continuous combined | | PMDD treatment | Yaz | FDA-approved indication | | Acne treatment | Yaz | FDA-approved for moderate acne |

Safety Considerations:

• Hyperkalemia risk: Antimineralocorticoid effect can increase potassium
• VTE controversy: Some studies suggest higher VTE risk vs. levonorgestrel; others show no difference
• Contraindicated: Renal impairment, adrenal insufficiency, hepatic impairment

Current FDA-Approved Products (U.S.):

1.2 Chemical and Pharmacological Classification

Chemical Name: 6β,7β,15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone Molecular Formula: C₂₄H₃₀O₃ Molecular Weight: 366.49 g/mol CAS Number: 67392-87-4

Classification:

• Drug Class: Progestin (synthetic progesterone analogue)
• Subclass: Spirolactone derivative (17α-spirolactone)
• Generation: Fourth-generation progestin
• Structural Relationship: Derived from spironolactone (aldosterone antagonist)
• Route: Oral

Structural Characteristics:

Unlike other progestins, drospirenone is NOT derived from testosterone or progesterone. It is a 17α-spirolactone derivative of spironolactone.

Comparison to Other Progestin Structures:

1.3 Historical Background

Development Timeline:

• 1976: Drospirenone patented by Schering AG (Germany)
• 1987: First clinical studies in HRT combinations
• 2000: First drospirenone product (with EE) introduced in Europe
• 2001: Yasmin (DRSP/EE) approved by FDA for contraception
• 2006: Yaz (DRSP/EE with 24/4 regimen) approved by FDA
• 2006: FDA approves Yaz for PMDD treatment
• 2007: FDA approves Yaz for moderate acne
• 2005: Angeliq (DRSP/E2) approved for menopausal HRT
• 2012: Lower-dose Angeliq (0.25 mg DRSP/0.5 mg E2) approved
• 2019: Slynd (drospirenone-only POP) approved by FDA

Key Milestones:

1. First spironolactone-derived progestin: Unique mechanism among contraceptives
2. First progestin with antimineralocorticoid activity: Addresses estrogen-related bloating
3. First OCP approved for PMDD: Yaz received FDA indication in 2006
4. First progestin-only pill with 24-hour missed pill window: Slynd (2019)

1.4 Clinical Context and Rationale

Why Drospirenone Is Unique:

1. Antimineralocorticoid activity: Counteracts estrogen-induced fluid retention
2. Anti-androgenic activity: Improves acne, seborrhea, hirsutism
3. No androgenic effects: Unlike levonorgestrel, norgestrel, norethindrone
4. PMDD treatment: Only OCP with FDA approval for PMDD
5. Longer half-life: Allows more forgiving dosing with Slynd

When Drospirenone Is Preferred:

When Drospirenone May Be Less Suitable:

2. Mechanism of Action

2.1 Molecular Mechanism

Progesterone Receptor Agonism:

Drospirenone binds to and activates progesterone receptors (PR), inducing typical progestogenic effects:

1. Receptor binding: DRSP binds cytoplasmic PR (PR-A and PR-B isoforms)
2. Nuclear translocation: Ligand-receptor complex enters nucleus
3. Gene transcription: Activates/represses progesterone-responsive genes
4. Endometrial effects: Transforms proliferative to secretory endometrium

Relative Progestogenic Potency:

• DRSP progestogenic potency ≈ norethisterone acetate
• Effective for endometrial protection at HRT doses (0.25-0.5 mg/day)
• Effective for ovulation inhibition at contraceptive doses (3-4 mg/day)

2.2 Receptor Selectivity Profile

Unique Multi-Receptor Activity:

Antimineralocorticoid Activity:

• Potency: 5-8 times higher affinity for MR than spironolactone
• Equivalence: DRSP 3 mg ≈ spironolactone 25 mg
• Mechanism: Competitive antagonism at renal mineralocorticoid receptors
• Effects:
  • Decreased sodium reabsorption
  • Increased potassium retention
  • Mild diuretic effect
  • Reduced fluid retention
  • Possible modest blood pressure reduction

Anti-Androgenic Activity:

• Potency: Approximately 30% of cyproterone acetate
• Mechanism: Competitive antagonism at androgen receptors
• Effects:
  • Reduced sebum production
  • Improvement in acne
  • Reduction in hirsutism
  • Does not lower testosterone (blocks receptor only)

2.3 Contraceptive Mechanisms

Combined Oral Contraceptives (Yaz, Yasmin):

Progestin-Only Pill (Slynd):

Key Difference from Traditional POPs:

Unlike norethindrone/norgestrel POPs that rely mainly on cervical mucus (with inconsistent ovulation inhibition), Slynd's 4 mg dose consistently inhibits ovulation, allowing the 24-hour missed pill window.

2.4 HRT Mechanisms (Angeliq)

Endometrial Protection:

• DRSP opposes estrogen-induced endometrial proliferation
• Transforms proliferative to secretory epithelium
• Prevents endometrial hyperplasia in women with intact uterus
• Continuous combined regimen typically leads to amenorrhea

Vasomotor Symptom Relief:

• Primarily from estradiol component
• DRSP does not interfere with estrogen's beneficial effects
• Antimineralocorticoid effect may reduce estrogen-associated bloating

Cardiovascular Effects:

• DRSP may have mild blood pressure-lowering effect
• Antimineralocorticoid activity could benefit women with hypertension
• Studies show modest BP reduction with Angeliq

2.5 Pharmacological Effects by System

Cardiovascular System:

Metabolic Effects:

Dermatological Effects:

3. Indications and Uses

3.1 FDA-Approved Indications

Yaz (DRSP 3 mg + EE 20 mcg - 24/4 regimen):

1. Prevention of pregnancy
2. Treatment of symptoms of premenstrual dysphoric disorder (PMDD) - in women who choose OCP for contraception
3. Treatment of moderate acne vulgaris - in women ≥14 years who choose OCP for contraception

Yasmin (DRSP 3 mg + EE 30 mcg - 21/7 regimen):

1. Prevention of pregnancy

Beyaz (DRSP 3 mg + EE 20 mcg + levomefolate - 24/4 regimen):

1. Prevention of pregnancy
2. Treatment of PMDD (same as Yaz)
3. Treatment of moderate acne (same as Yaz)
4. Folate supplementation for women who choose OCP

Slynd (DRSP 4 mg - 24/4 regimen):

1. Prevention of pregnancy (progestin-only)

Angeliq (DRSP + E2):

1. Treatment of moderate to severe vasomotor symptoms due to menopause - in women with a uterus
2. Treatment of moderate to severe vulvar and vaginal atrophy (0.5 mg DRSP/1 mg E2 only)

3.2 Available Formulations

Combined Oral Contraceptives:

Progestin-Only Pill:

Menopausal HRT:

3.3 Off-Label Uses

Dermatology:

Endocrinology:

Other:

3.4 Comparison to Other Progestins by Indication

4. Dosing and Administration

4.1 Combined Oral Contraceptives

Yaz/Beyaz (24/4 Regimen):

Administration:

• Take one tablet daily at same time
• Start on Day 1 of menstrual cycle OR first Sunday after menses
• Take continuously; start new pack immediately after completing previous

Yasmin (21/7 Regimen):

4.2 Progestin-Only Pill (Slynd)

Dosing:

Key Features:

Missed Dose Management (Slynd):

4.3 Menopausal HRT (Angeliq)

Lower Dose (0.25 mg DRSP/0.5 mg E2):

• Indication: Vasomotor symptoms only
• Dosing: One tablet daily without interruption
• Typical use: Continuous combined regimen (no withdrawal bleed)

Higher Dose (0.5 mg DRSP/1 mg E2):

• Indication: Vasomotor symptoms + vulvar/vaginal atrophy
• Dosing: One tablet daily without interruption
• Typical use: Continuous combined regimen

Administration:

• Take at same time daily with or without food
• Start immediately if no recent HRT
• Switch from sequential HRT after withdrawal bleed completes

Duration:

• Use lowest effective dose for shortest duration
• Reassess need annually
• Gradually taper when discontinuing

4.4 Dose Adjustments

Hepatic Impairment:

Renal Impairment:

Adrenal Insufficiency:

• Contraindicated - Cannot adequately regulate potassium

Drug Interactions (CYP3A4):

4.5 Special Dosing Considerations

Starting After Pregnancy:

Switching from Other Contraceptives:

5. Pharmacokinetics and Pharmacodynamics

5.1 Absorption

Absorption Notes:

• Absorption is rapid and nearly complete
• Peak concentrations reached within 1-2 hours
• Food does not significantly affect absorption
• Can be taken with or without meals

5.2 Distribution

Distribution Notes:

• Unlike levonorgestrel, drospirenone does NOT bind to SHBG
• Binding is primarily to serum albumin
• Distribution phase half-life: 1.6-2 hours

5.3 Metabolism

Major Metabolic Pathways:

Key Metabolic Features:

• Major metabolism is CYP450-independent (lactone ring opening, sulfation)
• Minor CYP3A4 involvement - less susceptible to typical enzyme inducers than other progestins
• Both major metabolites are pharmacologically inactive

CYP3A4 Drug Interactions:

Despite minor CYP3A4 involvement:

• Strong CYP3A4 inhibitors (ketoconazole): ↑ DRSP AUC 2-3 fold
• CYP3A4 inducers (rifampin): May ↓ DRSP levels (less effect than on other progestins)

5.4 Elimination

Clinical Implications:

• Long half-life (25-33 hours) allows once-daily dosing
• 24-hour missed pill window (Slynd) is possible due to sustained levels
• Steady-state achieved in 7-10 days
• Accumulation: 1.5-2 fold with continuous dosing

5.5 Pharmacodynamic Effects

Ovulation Inhibition:

Endometrial Effects:

• Secretory transformation begins within days
• Decidualization with continued use
• Typical result: thin endometrium, amenorrhea (especially HRT)

Cervical Mucus:

• Thickening begins within 24-48 hours
• Provides secondary contraceptive protection

Antimineralocorticoid Effects:

5.6 Pharmacokinetic Comparison

6. Side Effects and Safety Profile

6.1 Common Side Effects

Combined Oral Contraceptives (Yaz, Yasmin):

Progestin-Only Pill (Slynd):

Menopausal HRT (Angeliq):

6.2 Serious Adverse Effects

Hyperkalemia:

FDA Warning:

DRSP 3 mg has antimineralocorticoid activity equivalent to spironolactone 25 mg. DRSP-containing products should not be used in patients with conditions that predispose to hyperkalemia.

Venous Thromboembolism (VTE):

FDA Label Statement:

Epidemiologic studies have shown that the risk of VTE with DRSP-containing OCPs may be higher than with levonorgestrel-containing OCPs. Before initiating use of DRSP-containing products, consider the patient's risk factors for VTE.

Arterial Thromboembolic Events:

• Stroke and MI risk similar to other COCs
• Risk increased with smoking, especially age >35
• Hypertension increases risk

Hepatic Effects:

• Contraindicated in hepatic impairment
• Rare: hepatic adenomas (class effect with OCPs)

6.3 Unique Benefits vs. Other Progestins

Anti-Androgenic Benefits:

Antimineralocorticoid Benefits:

6.4 Comparison: Side Effect Profile vs. Other Progestins

6.5 Bleeding Pattern Effects

Combined OCPs (Yaz 24/4):

Progestin-Only (Slynd):

Menopausal HRT (Angeliq):

7. Drug Interactions

7.1 Drugs That Increase Potassium (HIGH PRIORITY)

Risk of Hyperkalemia with Concurrent Use:

Monitoring Recommendations:

• Check serum potassium during first cycle in women taking above medications chronically
• Repeat monitoring if doses change
• Contraindicated if baseline K+ elevated or renal impairment present

7.2 CYP3A4 Interactions

Strong CYP3A4 Inhibitors (Increase DRSP Levels):

Clinical Note: Unlike levonorgestrel, DRSP's major metabolic pathways are CYP450-independent, so the impact of CYP3A4 inhibitors is less dramatic. However, moderate increases in DRSP levels can occur.

CYP3A4 Inducers (Decrease DRSP Levels):

7.3 Effects of Drospirenone on Other Drugs

Important: Lamotrigine Interaction

• EE component (not DRSP alone) increases lamotrigine clearance
• Monitor seizure control when starting/stopping COC
• May need to ↑ lamotrigine dose during active pills
• Slynd (DRSP alone) has less effect on lamotrigine

7.4 Antibiotic Interactions

No Significant Interactions with Most Antibiotics:

Exception - Rifamycins:

• Rifampin, rifabutin, rifapentine are CYP3A4 inducers
• May reduce DRSP efficacy
• Use backup contraception or alternative method

7.5 Complete Drug Interaction Summary

8. Contraindications and Precautions

8.1 Absolute Contraindications

All DRSP-Containing Products:

COCs (Yaz, Yasmin) - Additional:

POP (Slynd) - Additional:

HRT (Angeliq) - Additional:

Same as COCs regarding VTE, arterial disease, breast cancer, liver tumors

8.2 Relative Contraindications (Use with Caution)

8.3 US Medical Eligibility Criteria (US MEC)

DRSP-Containing COCs:

DRSP-Containing POP (Slynd):

8.4 Specific Warnings

Hyperkalemia Warning (FDA Black Box Equivalent):

Products containing drospirenone may cause hyperkalemia in high-risk patients. Monitor serum potassium in women taking medications that may increase potassium (ACE inhibitors, ARBs, K+-sparing diuretics, NSAIDs, potassium supplements) during the first treatment cycle.

VTE Warning:

DRSP-containing COCs may be associated with higher risk of VTE compared to some other progestins. Evaluate each patient's VTE risk factors before prescribing.

Cardiovascular Warning:

Smoking increases the risk of serious cardiovascular events from COC use. Women over 35 who smoke should not use COCs.

9. Special Populations

9.1 Pregnancy

FDA Pregnancy Category: X (COCs, HRT) / Contraindicated

9.2 Breastfeeding

COCs (Yaz, Yasmin):

POP (Slynd):

9.3 Adolescent

Contraception (Yaz/Yasmin/Slynd):

Counseling:

• Anti-androgenic benefits for acne/PMDD
• VTE risk education
• Importance of consistent use (though wider window with Slynd)
• Does not protect against STIs

9.4 Perimenopausal

Contraception Considerations:

9.5 Postmenopausal (Angeliq)

9.6 Hepatic Impairment

Rationale: Drospirenone is metabolized hepatically. Impaired metabolism increases drug exposure and potential hepatotoxicity.

9.7 Renal Impairment

Rationale: Renal impairment prevents adequate potassium excretion, increasing hyperkalemia risk with antimineralocorticoid drugs.

9.8 Transgender Individuals

Male-to-Female (Transfeminine):

• DRSP may be used for progestin component of feminizing therapy
• Anti-androgenic properties may enhance feminization
• Typically combined with estrogen
• Monitor potassium if using spironolactone concurrently

Female-to-Male (Transmasculine):

• Not typically used (testosterone is standard)
• May be used for menstrual suppression if uterus present

10. Monitoring and Follow-Up

10.1 Baseline Assessment

Before Starting DRSP-Containing Contraception:

Before Starting Angeliq (HRT):

10.2 Potassium Monitoring

Who Needs Monitoring:

When to Recheck:

• If medication doses change
• If symptoms of hyperkalemia develop (muscle weakness, palpitations)
• Annually for high-risk patients

10.3 Ongoing Monitoring

Contraception (COCs):

Contraception (Slynd):

HRT (Angeliq):

10.4 When to Seek Medical Attention

10.5 Discontinuation

Reasons to Discontinue:

Post-Discontinuation:

• Fertility: Returns within 1-3 cycles
• VTE risk: Returns to baseline within weeks
• Vasomotor symptoms (HRT): May recur; consider taper

11. Cost and Accessibility

11.1 U.S. Pricing (2024-2025)

Combined Oral Contraceptives:

Insurance Coverage (COCs):

Progestin-Only Pill:

Menopausal HRT:

11.2 International Pricing

11.3 Assistance Programs

Manufacturer Programs:

Other Resources:

• Title X clinics: May provide at reduced/no cost
• Planned Parenthood: Sliding scale pricing
• State programs: Vary by state
• 340B pharmacies: Discounted pricing for eligible patients

11.4 Cost Comparison to Alternatives

Value Considerations:

• Generic DRSP/EE offers anti-androgenic benefits at affordable prices
• Slynd's 24-hour window provides convenience value
• Angeliq's BP-lowering effect may be valuable for hypertensive women

11.5 Accessibility Considerations

Prescription Requirements:

Geographic Availability:

• U.S.: Widely available at all pharmacies
• International: Yasmin widely available; Slynd limited
• Generic availability: Extensive for Yaz/Yasmin; none for Slynd

12. Clinical Evidence and Efficacy

12.1 Contraceptive Efficacy

Combined Oral Contraceptives (Yaz, Yasmin):

Progestin-Only Pill (Slynd):

Key Studies:

1. Phase III clinical trials: Demonstrated non-inferiority to levonorgestrel COCs
2. Slynd trials: 4% typical-use failure rate; superior to norethindrone POP (7-9%)
3. Real-world studies: Efficacy maintained with 24-hour missed pill window

12.2 PMDD Efficacy (Yaz)

FDA Approval Basis:

Outcomes:

Mechanism of PMDD Benefit:

• Anti-androgenic effects may stabilize mood
• Antimineralocorticoid effects reduce bloating-related symptoms
• 24/4 regimen provides shorter hormone-free interval
• Combination of above effects unique to drospirenone

12.3 Acne Efficacy (Yaz)

FDA Approval Basis:

Mechanism:

• AR antagonism reduces sebum production
• SHBG increase (from EE) reduces free testosterone
• Net anti-androgenic effect superior to androgenic progestins

Comparison to Other Acne OCPs:

12.4 HRT Efficacy (Angeliq)

Vasomotor Symptoms:

Blood Pressure Effects:

Endometrial Safety:

12.5 Safety Evidence

Hyperkalemia Studies:

VTE Studies:

Absolute VTE Risk Context:

12.6 Comparative Effectiveness

Drospirenone vs. Other Progestins:

13. Comparison to Alternatives

13.1 Drospirenone vs. Other Progestins (Detailed)

13.2 Slynd vs. Other POPs

When to Choose Slynd:

• Need estrogen-free option with forgiving dosing
• Acne/hirsutism concerns
• PCOS
• Wider missed pill window important

When to Choose Opill:

• OTC access preferred
• Cost-conscious
• No concerns about androgenic effects

13.3 Angeliq vs. Other HRT Options

When to Choose Angeliq:

• Hypertension (mild) with menopause
• Desire for antimineralocorticoid benefits
• Androgenic concerns
• Oral route acceptable

When to Choose Transdermal HRT:

• VTE risk factors
• Migraine
• Hypertriglyceridemia

13.4 Decision Algorithm

Choosing Drospirenone COC (Yaz/Yasmin):

Does patient have:
- Acne that may benefit from anti-androgen? → Consider Yaz
- PMDD symptoms? → Consider Yaz (FDA-approved)
- Fluid retention concerns? → DRSP may help
- No renal impairment? → DRSP appropriate
- No contraindications to estrogen? → COC appropriate

If yes to above → Drospirenone COC may be ideal choice

Choosing Slynd:

Does patient need:
- Estrogen-free contraception? → Consider Slynd
- Wider missed-pill window than traditional POP? → Slynd
- Anti-androgenic POP? → Only Slynd offers this
- No renal impairment? → Slynd appropriate

If VTE history/risk or breastfeeding → Slynd preferred over COC

13.5 Unique Position of Drospirenone

Only progestin that offers:

1. Antimineralocorticoid activity comparable to spironolactone
2. Anti-androgenic activity without glucocorticoid effects
3. FDA approval for PMDD treatment
4. 24-hour missed pill window (Slynd)
5. May reduce blood pressure (unlike other progestins)

Trade-offs:

1. Hyperkalemia monitoring in high-risk patients
2. Contraindicated in renal/hepatic/adrenal insufficiency
3. Possibly higher VTE risk (COCs)
4. Higher cost (especially Slynd, Angeliq)

14. Storage and Handling

14.1 Storage Requirements

All Drospirenone Products:

14.2 Handling Instructions

Dispensing:

• Keep in original packaging until use
• Dispense with patient information
• Check expiration date

Patient Instructions:

• Store at room temperature
• Keep in original blister pack
• Avoid extreme temperatures (hot car, freezing)
• Do not store in bathroom (humidity)
• Keep away from children

14.3 Stability

Shelf Life:

Stability Notes:

• Do not use after expiration date
• Discard if tablets are discolored or damaged
• No refrigeration required

14.4 Disposal

Proper Disposal Methods:

14.5 Travel Considerations

Traveling with DRSP Products:

Time Zone Adjustment:

• For COCs: Less critical due to 12-hour window
• For Slynd: 24-hour window provides flexibility
• Adjust timing gradually over several days for major changes

15. References

15.1 Primary Literature

1. Oelkers W, et al. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004;217(1-2):255-261.

2. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38.

3. Foidart JM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5(2):124-134.

4. Pearlstein TB, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414-421.

5. Maloney JM, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. Obstet Gynecol. 2008;112(4):773-781.

6. Archer DF, et al. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92(5):439-444.

7. Palacios S, et al. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015;18(Suppl 1):23-29.

15.2 Clinical Guidelines

1. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133(2):e128-e150.

2. Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC). MMWR. 2016;65(3):1-103. Updated 2020.

3. North American Menopause Society (NAMS). The 2022 hormone therapy position statement. Menopause. 2022;29(7):767-794.

4. American Academy of Dermatology. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.

5. International Society for Premenstrual Disorders. Management of premenstrual disorders. Am J Obstet Gynecol. 2020;222(4):B3-B15.

15.3 Drug Information Resources

1. Lexicomp. Drospirenone: Drug Information. UpToDate. 2024.

2. Micromedex. Drospirenone. IBM Watson Health. 2024.

3. American Hospital Formulary Service (AHFS). Drug Information. Drospirenone. 2024.

4. FDA. Yaz Prescribing Information. 2023.

5. FDA. Slynd Prescribing Information. 2022.

6. FDA. Angeliq Prescribing Information. 2023.

15.4 Pharmacokinetic Studies

1. Blode H, et al. Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women. Eur J Contracept Reprod Health Care. 2012;17(5):372-382.

2. Stanczyk FZ, et al. Pharmacokinetics of the hormone drospirenone. Contraception. 2003;67(2):75-81.

3. Rapkin AJ, et al. The pharmacology of drospirenone and its role as a progestogen. Expert Opin Drug Metab Toxicol. 2008;4(11):1457-1467.

15.5 Safety Studies

1. Dinger JC, et al. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344-354.

2. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel. BMJ. 2011;342:d2151.

3. Gronich N, et al. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183(18):E1319-E1325.

4. Dinger J, et al. The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharmacol. 2011;11:23.

15.6 PMDD and Acne Studies

1. Yonkers KA, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106(3):492-501.

2. Koltun W, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris. Contraception. 2008;77(4):249-256.

15.7 HRT Studies

1. White WB, et al. Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. J Am Soc Hypertens. 2008;2(1):20-27.

2. Preston RA, et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18(6):797-804.

3. Archer DF, et al. Endometrial effects of tibolone and drospirenone/estradiol continuous combined hormone replacement therapy. Int J Gynaecol Obstet. 2007;97(1):46-52.

15.8 Product Information

1. Bayer HealthCare Pharmaceuticals Inc. Yaz Prescribing Information. Current version.

2. Bayer HealthCare Pharmaceuticals Inc. Yasmin Prescribing Information. Current version.

3. Exeltis USA, Inc. Slynd Prescribing Information. Current version.

4. Bayer HealthCare Pharmaceuticals Inc. Angeliq Prescribing Information. Current version.

16. Goal Archetype Integration

16.1 Understanding Drospirenone's Unique Archetype Position

Drospirenone occupies a singular position among progestins due to its spironolactone-derived structure. Unlike testosterone-derived or progesterone-derived progestins, drospirenone functions as a triple-action hormone with progestogenic, anti-mineralocorticoid, and anti-androgenic activities simultaneously.

Archetype Classification:

16.2 Goal Archetype: Anti-Mineralocorticoid Progestin

Primary Goal Alignment:

This archetype addresses women whose primary concerns include:

• Fluid retention and bloating (cyclical or chronic)
• Mild hypertension requiring hormonal management
• Estrogen-related edema
• Weight stability concerns with hormonal therapy

Mechanism-to-Goal Mapping:

Quantified Anti-Mineralocorticoid Effect:

16.3 Goal Archetype: Contraception

Contraceptive Goal Stratification:

Contraceptive Goal Achievement Metrics:

16.4 Goal Archetype: Menopause Management

Menopausal Goal Alignment (Angeliq):

Menopause Subtype Selection:

16.5 Combined Archetype Scenarios

Scenario 1: Reproductive-Age Woman with PCOS

Scenario 2: Perimenopausal Woman with Hypertension

Scenario 3: Postmenopausal Woman on Antihypertensives

17. Age-Stratified Dosing

17.1 Overview of Age-Based Considerations

Drospirenone dosing remains relatively consistent across age groups, but clinical context, risk assessment, and product selection vary significantly by age and reproductive stage.

17.2 Adolescent Dosing (14-18 Years)

Approved Uses:

Dosing Considerations:

Adolescent-Specific Counseling:

• Emphasize STI protection (condoms) alongside contraception
• Discuss acne timeline (improvement typically by cycle 3-6)
• Address compliance strategies
• VTE warning signs education

17.3 Reproductive-Age Dosing (18-35 Years)

Standard Dosing:

Special Considerations:

17.4 Reproductive-Age Dosing (35-45 Years)

Risk-Stratified Selection:

Dosing Guidance:

• Standard dosing applies (no age-based adjustment)
• COC use acceptable in healthy non-smokers until menopause
• Consider transition to Slynd as VTE risk factors accumulate
• Monitor BP annually (more frequently if concerns)

17.5 Perimenopausal Dosing (45-55 Years)

Contraception Considerations:

Transition to HRT:

Perimenopausal Dosing:

17.6 Postmenopausal Dosing (>55 Years)

Angeliq Dosing:

Initiation Guidelines:

Duration Considerations:

Age-Specific Monitoring (Postmenopausal):

17.7 Age-Stratified Risk Summary

18. Drug Interactions - Potassium Concerns (Expanded)

18.1 Potassium Physiology and DRSP Effect

Normal Potassium Homeostasis:

DRSP-Induced K+ Increase:

18.2 High-Risk Drug Combinations

Tier 1: Highest Risk (Monitor Potassium Mandatory)

Monitoring Protocol for Tier 1:

1. Baseline potassium before starting DRSP
2. Repeat potassium at 7-14 days
3. Repeat at end of first cycle
4. Continue monitoring with dose changes

Tier 2: Moderate Risk (Monitor Potassium Recommended)

Monitoring Protocol for Tier 2:

1. Baseline potassium (if not recent)
2. Check potassium during first treatment cycle
3. Recheck if drug doses change
4. Annual monitoring if chronic concomitant use

Tier 3: Lower Risk (Consider Monitoring)

18.3 Practical Management Algorithms

Algorithm: Starting DRSP in Patient on ACE-I/ARB

Step 1: Verify current serum potassium
        → If K+ >5.0 mEq/L: Do NOT start DRSP
        → If K+ 4.5-5.0 mEq/L: Proceed with close monitoring
        → If K+ <4.5 mEq/L: Proceed with standard monitoring

Step 2: Start DRSP at standard dose

Step 3: Check potassium at 7-14 days
        → If K+ >5.5 mEq/L: Stop DRSP; evaluate alternatives
        → If K+ 5.0-5.5 mEq/L: Reduce K+ intake; repeat in 1 week
        → If K+ <5.0 mEq/L: Continue; recheck end of cycle

Step 4: End of first cycle
        → If K+ stable <5.0: Continue with annual monitoring
        → If K+ trending up: Consider alternative contraception/HRT

Algorithm: Starting DRSP in Patient on Spironolactone

Step 1: Evaluate necessity of both drugs
        → Can spironolactone be reduced/stopped?
        → Is DRSP's 25 mg equivalent sufficient alone?

Step 2: If both required:
        → Baseline potassium (must be <4.5 mEq/L)
        → Patient education on hyperkalemia symptoms
        → Close monitoring schedule

Step 3: Check potassium weekly for first month
        → Target K+ <5.0 mEq/L

Step 4: If K+ rises significantly:
        → Reduce spironolactone dose if possible
        → Consider alternative progestin
        → Do NOT simply continue without intervention

18.4 Signs and Symptoms of Hyperkalemia

Patient Education: When to Seek Care

ECG Changes with Hyperkalemia:

18.5 Special Population Considerations

Renal Function and Potassium:

Diabetes and Potassium:

Elderly Considerations (Angeliq Users):

18.6 Drug Interaction Quick Reference Card

Do NOT Combine (Relative Contraindication):

Combine with Monitoring:

Generally Safe (No Special Monitoring):

19. Bloodwork Impact

19.1 Expected Laboratory Changes

Electrolytes:

Renal Function:

19.2 Hormonal Bloodwork Impact

With Combined OCPs (Yaz/Yasmin):

With Progestin-Only (Slynd):

With HRT (Angeliq):

19.3 Lipid Panel Effects

Combined OCPs:

Drospirenone vs. Androgenic Progestins (Lipids):

Progestin-Only (Slynd):

HRT (Angeliq):

19.4 Glucose Metabolism

DRSP Advantage:

Unlike androgenic progestins (levonorgestrel, norgestrel), drospirenone does NOT adversely affect glucose metabolism. This makes it preferable for women with PCOS or prediabetes.

19.5 Coagulation Parameters

Combined OCPs (Estrogen Effect, Not DRSP):

Important: These changes are primarily due to the ESTROGEN component (EE), not drospirenone. Slynd (DRSP alone) has minimal coagulation impact.

Progestin-Only (Slynd):

19.6 Thyroid Function Tests

With Estrogen-Containing Products:

Clinical Guidance:

• Use FREE T4 and TSH for thyroid assessment in women on COCs/HRT
• Total T4/T3 will be artificially elevated
• If on levothyroxine, dose may need increase (due to TBG increase)

With Slynd (No Estrogen):

• Minimal TBG impact
• Total and free thyroid tests generally accurate

19.7 Hepatic Function

When to Check Liver Function:

19.8 Recommended Monitoring Schedule

Contraception (COCs and Slynd):

HRT (Angeliq):

19.9 Interpreting Results in DRSP Users

Common Lab Scenario Interpretations:

20. Protocol Integration

20.1 Drospirenone's Unique Protocol Position

Drospirenone stands alone among progestins due to its multi-receptor activity profile. This creates unique opportunities for protocol integration that no other progestin can match.

Unique Integration Characteristics:

20.2 Integration with Anti-Androgen Protocols

PCOS Management Protocol:

Integrated PCOS Protocol Example:

Mild-Moderate PCOS (no fertility desire):
- Yaz 24/4 (DRSP 3 mg + EE 20 mcg) — First-line
- If hirsutism persists at 6 months: Add spironolactone 25-50 mg
  (Note: monitor K+ with combination)
- Metformin if metabolic concerns

Severe Hirsutism:
- Yaz + Spironolactone 100 mg (K+ monitoring mandatory)
- OR: Yasmin + Spironolactone 100 mg
- Consider dermatological referrals (laser, eflornithine)

Anti-Androgen Replacement Calculation:

20.3 Integration with Cardiovascular Protocols

Hypertension + Contraception Protocol:

Hypertension + Menopause Protocol (Angeliq Integration):

Postmenopausal woman with controlled hypertension:
- Verify BP <140/90 on current regimen
- Baseline potassium (especially if on ACE-I/ARB)
- Start Angeliq (lower dose: 0.25 mg DRSP/0.5 mg E2)
- Monitor BP at 4 weeks, 8 weeks, then quarterly
- Check K+ at 1 month if on RAAS blocker
- May provide additional 2-4 mmHg systolic reduction

Protocol Consideration: DRSP + ACE-I/ARB:

Both drug classes affect RAAS. Combined protocol:

1. Baseline K+ must be <5.0 mEq/L
2. Start DRSP at standard dose
3. K+ check at 1-2 weeks
4. If K+ remains <5.0, continue with annual monitoring
5. If K+ rises >5.0, consider alternative progestin

20.4 Integration with Mental Health Protocols

PMDD Treatment Protocol:

Depression + Contraception Protocol:

DRSP and Mood - Evidence Summary:

• Yaz FDA-approved for PMDD (positive mood effects)
• Some women report mood benefits (anti-bloating, anti-androgen)
• Rare reports of depression exacerbation (as with any hormonal contraception)
• Monitor and individualize

20.5 Integration with Dermatology Protocols

Acne Management Protocol:

Isotretinoin Protocol with Mandatory Contraception:

Isotretinoin requires highly effective contraception:
- Yaz provides excellent contraception + additional acne benefit
- Start Yaz 1 month before isotretinoin
- Continue throughout isotretinoin course
- Continue 1 month after isotretinoin completion
- iPLEDGE documentation requirements apply

Hirsutism Treatment Protocol:

20.6 Integration with Fertility Transition Protocols

Pre-Conception Planning:

Post-Pregnancy Return to DRSP:

20.7 Integration with HRT Transition Protocols

Perimenopause to Menopause Transition:

Phase 1: Perimenopausal (still cycling)
- Continue contraception (fertility still possible)
- Slynd preferred if VTE risk factors
- Treat vasomotor symptoms with low-dose COC if appropriate

Phase 2: Menopause Suspected
- If on COC: Stop for 2 weeks, check FSH
- FSH >30 mIU/mL on 2 occasions = menopause likely
- Continue contraception until menopause confirmed

Phase 3: Menopause Confirmed (12 months amenorrhea)
- Transition from contraception to HRT if indicated
- Switch to Angeliq if E2+DRSP combination desired
- No overlap period needed

HRT Conversion Protocol:

20.8 Multi-Condition Protocol Examples

Example 1: 28-year-old with PCOS, Acne, Mild Hypertension

Assessment:
- Needs contraception
- Has hyperandrogenic symptoms (acne, hirsutism)
- BP 135/85 on no medications

Protocol:
- Start Yaz 24/4 (addresses contraception, acne, PCOS)
- Monitor BP at 4 weeks
- DRSP's antimineralocorticoid may help BP
- If BP normalizes: Continue Yaz long-term
- If BP increases: Switch to Slynd + add dermatology referral

Monitoring:
- BP at 1 month, 3 months, then annually
- Acne assessment at 3 and 6 months
- No routine K+ needed (no other K+-raising drugs)

Example 2: 52-year-old with Menopause, HTN on Lisinopril

Assessment:
- Vasomotor symptoms (10 hot flashes/day)
- Postmenopausal (14 months since LMP)
- BP controlled on lisinopril 10 mg

Protocol:
- Baseline K+ before starting (lisinopril interaction)
- Start Angeliq 0.25 mg DRSP / 0.5 mg E2
- K+ check at 2 weeks
- BP monitoring at 4 and 8 weeks
- May see additional BP reduction from DRSP

If K+ remains normal:
- Continue Angeliq
- Annual K+ and BP monitoring
- Mammogram per guidelines

If K+ rises (5.0-5.5):
- Dietary K+ restriction
- Consider reducing lisinopril if BP allows
- If K+ persists elevated: Consider alternative HRT

Example 3: 35-year-old with PMDD, Smoker, Needs Contraception

Assessment:
- PMDD symptoms confirmed
- Smokes 10 cigarettes/day
- Desires contraception

Protocol Challenge:
- Yaz is FDA-approved for PMDD but...
- Smoking at 35+ is relative contraindication for COCs (MEC 3)
- Need to balance risks

Options:
1. Strongly counsel smoking cessation
   - If quits: Yaz appropriate
   - If reduces: Slynd + SSRI for PMDD

2. Current smoker who won't quit:
   - Slynd for contraception
   - SSRI (sertraline, fluoxetine) for PMDD
   - Slynd does NOT have FDA approval for PMDD

Monitoring:
- Smoking status at each visit
- VTE warning signs education
- PMDD symptom tracking

20.9 Protocol Selection Decision Tree

Does patient need contraception?
├── YES
│   ├── Can patient use estrogen?
│   │   ├── YES → Consider Yaz/Yasmin
│   │   │   ├── Acne/PMDD? → Yaz (24/4)
│   │   │   ├── No special needs? → Yasmin (21/7) or Yaz
│   │   │   └── Folate supplementation desired? → Beyaz
│   │   │
│   │   └── NO (VTE risk, migraine w/aura, breastfeeding, smoker >35)
│   │       └── Slynd (only DRSP option without estrogen)
│   │
│   └── Hyperkalemia risk factors?
│       ├── YES → Monitor K+ first cycle
│       └── NO → Standard monitoring
│
└── NO (postmenopausal)
    └── Vasomotor symptoms + intact uterus?
        ├── YES → Consider Angeliq
        │   ├── HTN (mild)? → Angeliq may help
        │   ├── On ACE-I/ARB? → Monitor K+
        │   └── Renal impairment? → Contraindicated
        │
        └── NO → Other HRT options or no treatment

20.10 Unique Protocol Advantages of Drospirenone

Why DRSP May Be Chosen Over Other Progestins in Protocols:

Document Footer

Document Completion: 2025-12-26 Status: PAPER 39 OF 76 COMPLETE Total Length: ~1,750 lines (all 15 sections) Author: EpiqAminos Research Division

Revision History:

Next Paper: #40 - Dienogest - Hybrid progestin with strong antigonadotropic activity and endometriosis indication

End of Document